Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp)
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp)
The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award.
Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01)
Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01)
This Funding Opportunity Announcement encourages applications using community-engaged research methods to investigate the potential health risks of environmental exposures of concern to the community and to implement an environmental public health action plan based on research findings. The overall goal is to support changes to prevent or reduce exposure to harmful environmental exposures and improve the health of a community.
Validation and Demonstration of Devices for Environmental Exposure Assessment (R21/R33)
Validation and Demonstration of Devices for Environmental Exposure Assessment (R21/R33)
This funding opportunity announcement (FOA) is intended to facilitate the translation of prototype devices for characterization of personal exposures into field use by supporting a phased validation effort involving a partnership between tool developers and environmental epidemiologists. In the initial (R21) phase, the focus is on iterative refinement of the prototype based on evaluation in a pilot scale study. The goal of this phase is to demonstrate data quality, tool reliability, and usability in a real world and relevant setting. The second (R33) phase will involve larger scale application in a larger epidemiological study to demonstrate the added scientific value of the tool in terms of both improved exposure assessment and estimation of exposure-health outcome relationships.